Welcome to our dedicated page for Alto Neuroscienc SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alto Neuroscience filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing precision medicines for neuropsychiatric disorders. Form 8-K reports cover operating and financial results, clinical updates for programs such as ALTO-101 and ALTO-207, and material definitive agreements tied to private placements of common stock and pre-funded warrants.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and proposed amendments to the company’s equity incentive and employee stock purchase plans. The filings also identify ANRO common stock registered on the New York Stock Exchange and the company’s emerging growth company status.
Alto Neuroscience, Inc. director Andrew Craig Miller received a grant of stock options covering 26,000 shares of common stock at an exercise price of $20.44 per share. These options vest in 36 equal monthly installments starting on June 27, 2026, and were awarded under the company’s Non-Employee Director Compensation Policy, with no cash paid by the director for the grant.
Alto Neuroscience, Inc. director Andrew Craig Miller filed an initial Form 3 reporting his status as a director of the company. The excerpt shows no reported common stock or derivative holdings and no buy, sell, or other insider transactions associated with this filing.
Alto Neuroscience, Inc. appointed Andrew Miller, Ph.D. to its Board of Directors as a Class III director, filling a seventh board seat for a term ending at the 2027 annual stockholder meeting. He was also named to the Nominating and Corporate Governance Committee and deemed independent under NYSE and SEC rules.
As a non-employee director, Dr. Miller will receive an initial stock option for up to 48,200 shares or options valued at up to $400,000 by Black‑Scholes, plus ongoing annual option grants and cash retainers for board and committee service under the company’s Non-Employee Director Compensation Policy.
Alto Neuroscience, Inc. President and CEO Amit Etkin reported a bona fide gift of 400,000 shares of Common Stock on May 14, 2026. The shares were transferred for estate planning purposes to the Bard on Haven Trust, an irrevocable trust for the benefit of his spouse and children, for no consideration. The trustee is independent, and Etkin has no voting, dispositive, or pecuniary interest in the trust’s holdings. After the gift, he directly holds 833,949 shares of Alto Neuroscience common stock.
Alto Neuroscience, Inc. Amendment No. 1 to a Schedule 13G/A reports that Vestal Point Capital and affiliated reporting person Ryan Wilder beneficially hold 2,064,075 shares of Common Stock, representing 6.5% of the class. The filing cites 31,945,516 shares outstanding as of March 9, 2026 as the basis for the percentage. The statement lists shared voting and dispositive power over the 2,064,075 shares and provides the reporters' business address and CUSIP 02157Q109. The filing is signed by Ryan Wilder on behalf of Vestal Point Capital, LLC and individually with signature dates of 05/15/2026.
Alto Neuroscience, Inc. Schedule 13G/A amendment reports that Point72-related entities and Steven A. Cohen beneficially owned 1,170,865 shares of Common Stock, equal to 3.7% of the class as of the close of business on March 31, 2026.
The filing breaks holdings across affiliates: Point72 Asset Management and Point72 Capital Advisors report 503,087 shares (1.6%), and Point72 Biotech (with related entities) reports 667,778 shares (2.1%). Ownership is reported as shared voting and dispositive power; beneficial ownership is asserted through control relationships and advisory arrangements.
Alto Neuroscience ownership filing: Commodore Capital LP, Commodore Capital Master LP, and principals report beneficial ownership of 3,588,180 shares of common stock, reflecting direct holdings plus shares issuable upon exercise of a pre-funded warrant. The filing states an effective Beneficial Ownership Limitation of 9.99% and ties ownership percentages to 35,052,731 shares outstanding as of March 31, 2026. The report is a joint Schedule 13G/A filing by the investment manager and two managing partners and lists related voting and dispositive powers.
Alto Neuroscience, Inc. Schedule 13G reports that Sirenia Capital Management and Alex Silverstein together beneficially hold 2,591,587 shares of Common Stock, representing 7.9% of the class assuming exercise of certain warrants.
Securities outstanding were 31,945,516 shares as of March 16, 2026, per the referenced proxy statement. The position includes 787,043 shares issuable upon exercise of warrants, and the filing is made under Rule 13d-1(k) as a joint filing.
Alto Neuroscience director Ramiro Sanchez received a grant of stock options for 10,958 shares of common stock. The options have an exercise price of $24.63 per share and expire on May 11, 2036. All 10,958 underlying shares will vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as he remains in continuous service. The options were issued under Alto Neuroscience’s Non-Employee Director Compensation Policy, and Sanchez paid no cash consideration for this award. Following this grant, he holds 10,958 derivative securities directly.
Alto Neuroscience, Inc. director Christopher Nixon Cox received a grant of stock options for 10,958 shares of common stock at an exercise price of $24.63 per share. These options vest on the earlier of one year from grant or the company’s next annual meeting, provided he continues in service, and were issued under the non-employee director compensation policy without any cash payment from him. Following this grant, he holds 10,958 stock options directly.